Biology Reference
In-Depth Information
Industry-sponsored clinical trials are currently largely focusing on evaluation of
HCMV vaccines in HSC and solid organ transplant patients at high risk for HCMV
viremia and disease. While such studies advance the field, negative data from
these studies should be interpreted cautiously, and such data cannot automatically
be extrapolated toward the problem of prevention of congenital HCMV infection
and disease. Industry sponsors, funding agencies, and regulatory bodies must
work together to dramatically accelerate the pace of clinical trials for this urgent
public health priority.
References
Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML, Best AM (1995) Immunity
induced by primary human cytomegalovirus infection protects against secondary infection
among women of childbearing age. J Infect Dis 171:26-32
Adler SP, Plotkin SA, Gonczol E, Cadoz M, Meric C, Wang JB, Dellamonica P, Best AM,
Zahradnik J, Pincus S, Berencsi K, Cox WI, Gyulai Z (1999) A canarypox vector expressing
cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated
CMV vaccine (Towne). J Infect Dis 180:843-846
Adler B, Scrivano L, Ruzcics Z, Rupp B, Sinzger C, Koszinowski U (2006) Role of human cytome-
galovirus UL131A in cell type-specific virus entry and release. J Gen Virol 87:2451-2460
Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R; National Vaccine Advisory Committee
(2004) Vaccine development to prevent cytomegalovirus disease: report from the National
Vaccine Advisory Committee. Clin Infect Dis 39:233-239
BenMohamed L, Krishnan R, Longmate J, Auge C, Low L, Primus J, Diamond DJ (2000)
Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic
mice: dependence on HLA class II restricted T(H) response. Hum Immunol 61:764-779
Berencsi K, Gyulai Z, Gonczol E, Pincus S, Cox WI, Michelson S, Kari L, Meric C, Cadoz M,
Zahradnik J, Starr S, Plotkin S (2001) A canarypox vector-expressing cytomegalovirus (CMV)
phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronega-
tive subjects. J Infect Dis 183:1171-1179
Bernstein DI, Schleiss MR, Berencsi K, Gonczol E, Dickey M, Khoury P, Cadoz M, Meric C,
Zahradnik J, Duliege AM, Plotkin S (2002) Effect of previous or simultaneous immunization
with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subu-
nit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis 185:686-690
Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J (2003) Cytomegalovirus
in hematopoietic stem cell transplant recipients: current status, known challenges, and future
strategies. Biol Blood Marrow Transplant 9:543-558
Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ (2001) Intrauterine transmission of
cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med
344:1366-1371
Britt WJ, Vugler L, Butfiloski EJ, Stephens EB (1990) Cell surface expression of human cytome-
galovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in
analysis of the human neutralizing antibody response. J Virol 64:1079-1085
Cannon MJ, Davis KF (2005) Washing our hands of the congenital cytomegalovirus disease epi-
demic. BMC Public Health 5:70
Cicin-Sain L, Brune W, Bubic I, Jonjic S, Koszinowski UH (2003) Vaccination of mice with bac-
teria carrying a cloned herpesvirus genome reconstituted in vivo. J Virol 77:8249-8255
Colugnati FA, Staras SA, Dollard SC, Cannon MJ (2007) Incidence of cytomegalovirus infection
among the general population and pregnant women in the United States. BMC Infect Dis 7:71
